High Frequency of Mutations in BTK and PLCG2 in Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib Therapy
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA(2018)
Abstract
Targeted therapies such as the BTK inhibitor Ibrutinib profoundly changed the management of patients with CLL. Molecular mechanisms underlying disease progression on therapy are being actively explored, and mutations in BTK or PLCγ2 gene have been identified as an important one.
MoreTranslated text
Key words
chronic lymphocytic leukemia,ibrutinib,mutations,resistance
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined